^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | ORIC-114 (HER2 exon 20 mutation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ph 1/2 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Excerpt:
...- Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/overexpression as determined by an immunohistochemistry (IHC) or an in situ hybridization (ISH) test...
Trial ID:
Source:
Title:
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Published date:
10/16/2023
Excerpt:
ORIC-114-01 (NCT05315700) is an ongoing i3+3 dose escalation (Part I), followed by dose optimization (Part II), and dose expansion (Part III) study in patients with advanced solid tumors harboring an EGFR or HER2 alteration who have exhausted available treatment options, including patients with active brain metastases....ORIC-114 has demonstrated an acceptable safety profile and preliminary antitumor activity, including in the CNS...
Trial ID:
